GRZAN Medical Device Regulatory Services for the Mexican Market

1. Key takeaways

GRZAN delivers Mexico projects through a direct link with its domestic registration team combined with coordination through licensed local partners in Mexico. The service covers the full chain from classification determination to post-market maintenance, and the core of the offer is that clients complete compliant market access without establishing a Mexican company, while the holding structure keeps control of the registration certificate in the client’s hands. Working this way, the regulatory argument is prepared by the team that will also defend it in inquiries, and the local partner supplies the on-the-ground actions that Mexican law assigns to local subjects.

• Delivery combines a domestic registration team with licensed local partners in Mexico.
• The service chain runs from classification through dossier submission to post-market and renewal.
• The holding arrangement is independent of the commercial channel, so clients keep control of the certificate.
• The simplified pathway with a 30-working-day channel is the main lever for shortening timelines.
• Label replacement against the 2027-05-14 date and tecnovigilance readiness are planned as part of the same programme.

2. Legal basis

Each service stage corresponds to a defined regulatory step, listed in the table below with the underlying source and the delivered content. The mapping is the reason the engagement is structured by stages rather than as a single undifferentiated filing service: classification errors propagate into the dossier, pathway choice changes the timeline, and post-market duties start on the issuance date, so the stages must be sequenced rather than bundled.

3. Expert insights

Insight one: the holding arrangement is the watershed of the service. Holding the certificate through the commercial channel party creates transfer risk. GRZAN uses a holding structure that is independent of the channel, so that clients retain their market access entitlement even when the channel changes, and the value of that design becomes visible precisely when commercial relationships shift. The same structure also simplifies transfers, because the certificate does not move when the distributor does.

Insight two: the simplified pathway is the main lever for shortening the timeline. Products holding approvals from reference regulatory authorities such as the FDA, CE, Health Canada, and PMDA can apply through the 30 working day channel. Assessing the four elements (authority, procedure type, 5 year validity, product consistency) is the first step, and the outcome of that assessment determines whether the pathway is realistic for the specific product. Products that fail one of the four elements should still be filed through the standard route rather than waiting for a pathway that will not open.

Insight three: MDSAP spreads system costs across markets. Companies that already hold MDSAP because of Canada, where it has been mandatory since 2019-01-01, and of the United States and other markets can reuse their audit reports in Mexico as system evidence. One audit therefore serves several destinations, and the marginal cost of the Mexican system file falls accordingly. The coordination work lies in mapping each audit finding onto the NOM-241 requirements so the equivalence argument is documented rather than implied.

Insight four: the 2027 label replacement is the most concentrated workload of the next two years. NOM-137-SSA1-2025 takes effect around 2027-05-14, adds mandatory content such as intended use, production date, and catalogue number / model / version number, and requires consistency with the registration dossier, which pulls registration changes along with the artwork. Planning backwards from that date is the only way to keep both tracks on schedule, and the artwork work should start well ahead of the dossier update to leave room for review cycles.

Insight five: tecnovigilance is the line most likely to break. Article 6.7.1 of NOM-240-SSA1-2012 places the duty on the holder, and it applies to all risk classes. Service capability shows in the establishment of the unit, the appointment of the responsible person, and the execution of the three-tier deadlines, and these are the items a client should test when evaluating any provider, including this one.

4. Practical recommendations

• Start the project with the two assessments of classification determination and pathway selection before discussing timeline and budget.
• Decide the holding structure at the design stage, and do not begin from the channel party.
• Schedule products with reference approvals onto the simplified pathway first, and lock the product configuration to be consistent with the reference version.
• Plan the label replacement backwards from 2027-05-14, coordinated with the registration change.
• Put the tecnovigilancia unit into operation on the day the registration is issued.

5. Verification checklist

• □ The classification argument and pathway selection are complete
• □ The holding structure is set as an independent third party
• □ The four elements of the reference approval have been assessed
• □ Reuse of MDSAP as system evidence has been assessed
• □ The label replacement is planned backwards from 2027-05-14
• □ The tecnovigilancia unit start date is aligned with the registration issuance date

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Mexican market. Our team manages COFEPRIS registrations and equivalence (equivalencia) reviews, coordinates third-party authorised centre routes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com